Evotec OAI Names Ian Hunneyball President of Discovery Services and Member of the Management Board
Hamburg, Germany | Abingdon, UK - Evotec OAI AG, Hamburg, Germany (Neuer Markt: EVT), a partner for integrated high-value-added drug discovery to the pharmaceutical and biotechnology industries, today announced the appointment of Ian M. Hunneyball as President of Discovery Services, the Company's core business, and a member of its Management Board. He will lead Evotec OAI's chemistry operations in Abingdon, UK, and the biology services operations in Hamburg, Germany. Evotec OAI has created this position as a consequence of increasing demand for integrated "Target-to-IND-Services" covering all biology and chemistry aspects of drug discovery.
Dr Hunneyball, 52, will join Evotec OAI with effect from January 1, 2003. He brings more than 24 years' of business experience in the pharmaceutical and biotech industry to the company. Most recently, Dr. Hunneyball was Director of R&D at Entomed S.A., a French biotechnology company involved in the discovery and development of drugs derived from the biology of insects. He joined Knoll Pharmaceuticals Ltd. (BASF Pharma) in 1995, where he was Director of Research and Development. During his six years at Knoll he was responsible for all UK R&D activities. He oversaw the global development of two new chemical entities (flosequinan, sibutramine) from discovery through to registration. Dr Hunneyball has a Ph.D in medical biochemistry from the University of Birmingham, England.
The company also announced today that Sean Marett, 37, currently Chief Business Officer, will become Senior Vice President, Licensing and Negotiations, with effect from January 1, 2003, with responsibility for negotiating the Company's high-level partnership agreements. In his new position, he will no longer be member of the Management Board.
Joern Aldag, President and Chief Executive Officer of Evotec OAI, said: "With extensive experience in the pharmaceutical industry, Ian has built a thorough understanding of all aspects of the drug discovery and development chain. His excellent team leadership skills and strong commercial awareness will further strengthen our management team and make a significant contribution to the continued successful growth of our business as a partner for pharma and biotech customers. Sean Marett's appointment as head of licensing will greatly enhance our focus on this crucial area of our business."
About Evotec OAI AG
Evotec OAI offers a comprehensive range of high-value added services and products required to increase the efficiency and at the same time reduce the risk in the identification of new drugs. By integrating proprietary state-of-the-art technologies and processes in biology, chemistry and screening, the Company has established a unique position for all the critical elements in the drug discovery and development process - from target to clinical development. Due to its extensive know how and experience Evotec OAI is the ideal partner for pharma and biotech companies worldwide. To date, Evotec OAI has completed over 1,200 projects with 150 companies, including all of the top 20 global pharmaceutical companies and major biotechs.
The Company employs more than 600 people, primarily at its two main sites at Hamburg in Germany and Abingdon in the UK. Subsidiaries are located in Europe and North America. In 2001 Evotec OAI achieved revenues of EUR 63.2 million. Evotec OAI shares are listed on the Neuer Markt of the Frankfurt Stock Exchange since November 1999 (NM: EVT).